Pharmaceutical Grade Apremilast API CAS 608141-41-9

Grade: Pharmaceutical Grade

Factory Location: China

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: 100kg

Contract Manufacturing: CRO,CMO

Packaging Information: 5kg/drum

Delivery Lead Time: 15days

Sample Provided: yes

Payment Terms: T/T

Mechanism of Action

Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action in psoriatic arthritis patients and psoriasis patients is not well defined.

Indication

OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of:

• Adult patients with active psoriatic arthritis
• Patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.